Welcome to our dedicated page for Verastem news (Ticker: $VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verastem's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verastem's position in the market.
Rhea-AI Summary
Verastem Oncology appoints Dr. John Hayslip as Chief Medical Officer, bringing extensive oncology expertise to lead clinical programs and advance pipeline assets focused on RAS/MAPK pathway-driven cancers. Dr. Hayslip's appointment follows the departure of Louis J. Denis, M.D. The company aims to submit a rolling NDA for the avutometinib and defactinib combination in low-grade serous ovarian cancer in the first half of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
-
Rhea-AI Summary
GenFleet Therapeutics presents promising research findings on GFH375, a potent KRAS G12D inhibitor, at AACR Annual Meeting, with potential for treating KRAS G12D mutant cancers including brain metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary
Verastem Oncology (VSTM) grants stock options to new employees as an inducement material to their employment. The options allow the purchase of 35,000 shares at $11.73 per share, vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
Rhea-AI Summary
SGO 2024 findings reveal significant concerns among respondents regarding life expectancy, treatment side effects, and emotional well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary
Verastem Oncology (VSTM) reports progress in developing combination therapies for cancer, including Phase 3 trials and FDA Fast Track designation. Financial results for Q4 2023 and full year released.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
-
Rhea-AI Summary
Verastem Oncology (Nasdaq: VSTM) presented multiple oral and poster presentations at the SGO 2024 Annual Meeting on Women’s Cancer. The presentations included a late-breaking oral presentation of avutometinib and defactinib combination data from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Summary
Verastem Oncology receives FDA Orphan Drug Designation for avutometinib and defactinib in recurrent low-grade serous ovarian cancer, aiming for Accelerated Approval in 2024. The company is addressing a rare cancer with no approved treatments, impacting a significant patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
-
Rhea-AI Summary
Verastem Oncology announces promising preclinical data on GFH375 (VS-7375) and avutometinib-FAK inhibitor combination for pancreatic and colorectal cancer treatment. Partner GenFleet to submit IND in H1 2024. Key presentations at AACR Annual Meeting 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
-
Rhea-AI Summary
Verastem Oncology (VSTM) plans to submit an NDA for Accelerated Approval for the combination of avutometinib and defactinib in recurrent low-grade serous ovarian cancer in the first half of 2024. They also aim to provide data read-outs with avutometinib and defactinib combinations in KRAS G12C-mutant non-small cell lung cancer and frontline metastatic pancreatic cancer, as well as supporting their collaborator GenFleet in advancing oral KRAS G12D inhibitor GFH375/VS-7375 into a Phase 1 clinical trial this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
Rhea-AI Summary
Verastem Oncology (VSTM) announced that the FDA has granted Fast Track Designation to its investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the treatment of patients with KRAS G12C-mutant metastatic non-small cell lung cancer (NSCLC). Initial RAMP 203 trial results showed confirmed responses in both KRAS G12C inhibitor resistant and naïve patients. Enrollment is ongoing in the expansion phase, with updated results expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
Verastem, Inc.
Nasdaq:VSTM
VSTM Rankings
VSTM Stock Data
275.85M
13.68M
0.55%
66.74%
2.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NEEDHAM
About VSTM
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com